Joseph L. Izzo MD
Joseph L. Izzo
MD
Professor and Chief, Clinical Pharmacology
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Cardiac pharmacology; Cardiopulmonary physiology; Cardiovascular Disease; Clinical Research; Drug Development; Internal Medicine; Nephrology; Pathophysiology; Pathophysiology; pharmacodynamic; Pharmacotherapy
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
Find this physician on UBMDProfessional Summary:
(1) Role of the sympathoadrenal system in hypertension and cardiovascular disease
(2) Control of regional and systemic blood flow
(3) Mechanisms of vasoreactivity, including metabolic interactions
(4) Cardiovascular drug effects
(5) Outcomes of drug therapies
(6) Arterial mechanics
Education and Training:
- Fellowship, Clinical Associate Physician, National Heart, Lung and Blood Institute (1979)
- Residency, Internal Medicine, Barnes Hospital/Washington University (1974)
- Internship, Internal Medicine, Barnes Hospital/Washington University (1973)
- MD, Internal Medicine, Johns Hopkins University (1972)
- Biology/Biochemistry, Princeton University (1968)
Employment:
- Professor of Pharmacology and Toxicology, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1991-present)
- Professor of Medicine, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1990-present)
- Chief of Medicine, Erie County Medical Center (2004–2024)
- Associate Program Director, Internal Medicine Training Program, University York at Buffalo (2004–2008)
- Vice Chair for Research, Department of Medicine, State University of New York at Buffalo (1999–2006)
- Director, FDA Clinical Pharmacology Fellowship Training Program, University at Buffalo (1992–2002)
- Program Director, Internal Medicine Training Program B, State University of New York at Buffalo (1988–2001)
- Chairman, Department of Medicine, Millard Fillmore Health System (1988–1998)
- Adjunct Associate Professor of Medicine, University of Rochester School of Medicine (1988–1991)
- Associate Professor, Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (1988–1990)
- Associate Professor; Attending Physician, Department of Medicine, University of Rochester School of Medicine Faculty of Arts and Letters (1984–1988)
- Director, Hypertension Service, University of Rochester School of Medicine Jacobs School of Medicine & Biomedical Sciences (1980–1988)
- Assistant Professor of Medicine; Associate Physician, (Nephrology), University of Rochester School of Medicine School of Medicine (1979–1984)
- Guest Worker, Experimental Therapeutics Section, Hypertension Endocrine Branch, National Heart, Lung and Blood Institute, National Institutes of Health (1979–1980)
- Attending Physician, National Institutes of Health Bethesda Maryland (1975–1979)
- Staff Associate, Experimental Therapeutics Section, Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute, NIH Bethesda, Maryland (1975–1979)
- Physician, part time, Urgent Care Clinic, Columbia Medical Group (1975–1978)
- Consultant in Emergency Medicine and Acting Assistant Director of Emergency Services, Howard County General Hospital (1974–1975)
- Lecturer in Medicine, School of Health Services, Johns Hopkins University (1974–1975)
- Intern and Assistant Resident, Straight Medicine, Washington University, Barnes Hospital (1972–1974)
Awards and Honors:
- American Society of Hypertension, Marvin Moser Clinical Hypertension Award (2012)
- Who's Who (2011)
- American Society of Hypertension, Fellow (2010)
- American Society of Hyptertension, Hypertension Specialist (1999)
- Best Doctors in America (1996)
- American Heart Association, Fellow (1995)
- American College of Physicians, Fellow (1990)
- Fellow, High Blood Pressure Research Council, AHA (1984)
- Who's Who in Science (1984)
- Who's Who in the East (1984)
- Sinsheimer Scholar Award (1982)
- Buswell Fellow, University of Rochester (1979)
- Clinical Associate Physician Award, University of Rochester (1979)
- Hearst Foundation Senate Youth Fellow (1964)
- National Merit Scholarship Finalist (1964)
Research Expertise:
- New Research Expertise
Grants and Sponsored Research:
- February 2022–June 2026
TRANSCEND: A randomized, double-blind, placebo-controlled, parallel arm, multicenter, phase 2 study to evaluate the efficacy and safety of lorundrostat in subjects with uncontrolled hypertension on a standardized medication regimen.
Mineralys Pharmaceuticals
Role: Principal Investigator - February 2022–February 2026
TRANSCEND. An open-label extension study to assess the long-term safety, efficacy, and tolerability of Lorundrostat in subjects with uncontrolled hypertension
Mineralys Pharmaceuticals
Role: Principal Investigator - January 2024–October 2025
CYCLE 1. A phase 2, randomized, double-blind, placebo-controlled, dose finding study to assess the safety and effectiveness of Tovinontrine in patients with chronic heart failure with reduced ejection fraction.
Cardurion Pharmaceuticals
Role: Principal Investigator - January 2024–October 2025
CYCLE 2. A phase 2, randomized, double-blind, placebo-controlled clinical study to assess the safety and effectiveness of Tovinontrine in patients with chronic heart failure with preserved ejection fraction.
Cardurion Pharmaceuticals
Role: Principal Investigator - June 2001–December 2002
Hemodynamic Profiling of Carvedilol
Glaxo Smith-Kline
Role: Principal Investigator
$195,000 - October 1992–September 2002
Pilot Clinical Pharmacology Training Program
US Food and Drug Administration and USPHS
Role: Principal Investigator
$2,055,000 - January 1989–December 1994
Coronary Arrhythmia Suppression Trial
NHLBI, NIH
Role: Principal Investigator
$125,000 - January 1986–January 1988
Seasonal Blood Pressure Variation
American Heart Association, NYS Affiliate
Role: Principal Investigator
$49,000 - October 2026
ELEVATE HF: A Phase III, Randomized, Double-blind, Parallel-group, Placebocontrolled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF.
AstraZeneca Pharmaceuticals
Role: Principal Investigator - October 2026
ELEVATE-CKD: A Phase III, Randomized, Double-blind, Parallel-group, Placebocontrolled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease
AstraZeneca Pharmaceuticals
Role: Co-Investigator - August 2026
CALIBRATE-HF: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF)
Cardurion Pharmaceuticals
Role: Principal Investigator - April 2025
A safety, tolerability and biomarker trial of VS-041 in participants with heart failure with preserved ejection fraction (HFpEF)
VASA Pharmaceuticals
Role: Principal Investigator - March 2024
LUMINARA. A phase IIb, two cohort, randomized, placebo-controlled, double-blind, multi-center, dose-ranging study of AZD5462 in stable patients with chronic heart failure.
AstraZeneca Pharmaceuticals
Role: Principal Investigator
Journal Articles:
- Izzo, JL Jr, Srungavarapu SR, Khatri CP, Shalini FNU, Osmond PJ. (2026) Hemodynamic evolution of heart failure from hypertension: low stroke volume index and increased heart rate. Am J Hypertension (Oct) doi:doi.org/10.1093/ajh/hpag067
- Zannad F, O'Connor C, Butler J, McMullan C, Anstrom K, Barash I, Bonaca M, Borentain M, Corda S, Gates D, et al. (2026) Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. The Lancet (Sep), 406(25): 1682-4. doi:doi: 10.1016/S0140-6736(25)01682-4
- Izzo JL Jr. (2026) The sympathoadrenal system and the physiologic maintenance and pathologic sequelae of hypertension. Choices in Cardiology (Sep), 5(Suppl. 2): 17-20.
- Izzo JL Jr, Hong M, Hussain T, Osmond P. (2026) Blood pressure and vascular elasticity in patients with hyperaldosteronism during long-term, low-dose, amiloride-based therapy. J Clinical Hypertension (Greenwich) (Jul), 21(7): 922-8. doi:DOI: 10.1111/jch.13567
- David D. Berg, MD, MPH, Siddharth M. Patel, MD, MPH, Paul M. Haller, MD, PhD, Abby L. Cange, BS, Michael G. Palazzolo, MS, Andrea Bellavia, PhD, Julia F. Kuder, MA, Jan Belohlávek, MD, PhD, Akshay S. Desai, MD, MPH, Jaroslaw Drozdz, MD, PhD, Silvio E. Inzucchi, MD, John J.V. McMurray, MD, Béla Merkely, MD, PhD, Eileen O’Meara, MD, Subodh Verma, MD, PhD, Modele O. Ogunniyi, MD, MPH, Tomáš Drasnar, MD, Joseph L Izzo, MD, Balazs Sarman, MD, John E. McGinty, MD, Krishnan Ramanathan, MB, ChB, FRACP, FRCPC, Angel J. Mulkay, MD, Andrzej Przybylski, MD, PhD, Christian T. Ruff, MD, MPH, Michelle L. O’Donoghue, MD, MPH, Sabina A. Murphy, MPH, Marc S. Sabatine, MD, MPH,* Stephen D. Wiviott, MD* (*contributed equally). (2025) Dapagliflozin in Patients Hospitalized for Heart Failure. Circulation (Nov), 152(20): 1411-22.
- Butler J, McMullan C, Anstrom K, Barash I, Bonaca M, Borentain M, Corda S, Ezekowitz J, Gates D, Lam C, et al. (2025) Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. (Sep), 406(25): 1665-4.. doi:doi: 10.1016/S0140-6736(25)0
- Izzo, JL Jr and Srungavarapu SR. (2025) The hemodynamic basis of hypertensive vasculopathy, heart failure, and chronic kidney disease. Am J Hypertension (Sep), 38(11): 878-81. doi:doi.org/10.1093/ajh/hpag067
- Izzo, JL Jr, Mukhopadhyay D, Nagpal S, Osmond P. (2023) Impact of arterial location, pressure wave indicators, and measurement devices on arterial form factor and mean and central arterial pressure. J Human Hypertens (Oct), 10: 891-7. doi:doi: 10.1038/s41371-022-00791
- Izzo, JL. (2022) Blood pressure variability: mechanisms, measurement, subtypes, and clinical implications. Med Res Archives (Sep), 10(10)
- Izzo JL Jr. and Mitchell GF. (2021) Pitfalls of pulse wave analysis and oscillometric blood pressure derivatives. Hypertension (Sep), 78: 372-375. doi:doi:10.1161/HYPERTENSIONAHA.121.17228
- Mitchell GF, Solomon S, Shah A, Clagett B, Gang J, Izzo J, Abbas C. (2021) Hemodynamic effects of Sacubitril-Valsartan in patients with heart failure in the EVALUATE HF trial. Circ Heart Fail (Jul), 14 doi:DOI: 10.1161/circheartfailure.120.007891
- Izzo JL Jr, Anwar MA, Elsayed S, Osmond PJ, Gavish B. (2020) Dissociation of carotid and forearm pressure decay constants (tau), Windkessel compliances, and pulse wave velocities: implications for circulatory models. Artery Research (Jan), 25: 165-9..
- 193. Izzo JL Jr, Anwar MA, Elango K, Ahmed R, Osmond PJ. (2019) Decoupling of heart rate and blood pressure: hemodynamic counter-regulatory mechanisms and their implications. Artery Research (Dec), 25: 87-94.
- 192. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo JL, McCague K, Abbas CA, Rocha R, Mitchell GF for the EVALUATE-HF Investigators. (2019) Effects of Sacubitril-Valsartan Compared with Enalapril on Arterial Hemodynamics and Cardiac Remodeling in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA (Sep), 322(11): 1077-84.
- Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, and Seman L. (2019) Blood Pressure Effects of Empagliflozin in African Americans with Type 2 Diabetes and Hypertension. Circulation (Sep), 139: 2098-2109. doi:Accession Number: 30786754 DOI: 10.1161/circulationaha.118.036568
- Izzo JL Jr. (2019) Barriers to blood pressure control initiatives: Regional diversity, inadequate measurement techniques, guideline inconsistencies, and health disparities. J Clin Hypertens (Greenwich) (Feb), 21(2): 204-7. doi:Accession Number: 30609230 DOI: 10.1111/jch.13466
- Schwartz J, Feig PU, Izzo JL Jr. (2019) Effect of age and systolic blood pressure on 24-hour ambulatory (Mobil-O-Graph) oscillometric pulse wave velocity. Hypertension (Jan), 74(1): 111-6. doi:Accession Number: 31132952 DOI: 10.1161/hypertensionaha.119.12756
- Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope LM, Rump C, Mertens PR, Haller H. (2017) Predictors for the development of microalbuminuria and interaction with renal function. J Hypertens. (Dec), 35(12): 2501-2509..
- Izzo JL Jr and Gavish B. (2017) Reponse to "A Short Insight on Two Different Aspects of Arterial Stiffness"; Moving Forward or Backward?. American Journal of Hypertension (Sep), 30: e3-4. doi:doi: 10.1093/ajh/hpw203.
- Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J. (2017) Efficacy of LCZ696 and free combinations of valsartan and escalating doses of sacubitril in systolic hypertension. J Cardiovasc. Pharmacol. (Jun), 69(6): 374-381.
- Izzo JL Jr, Jia Y, Zappe DH, Jia Y, Hafeez K, Zhang J. (2017) Influence of Age and Race on the Blood Pressure Response to Valsartan, Hydrochlorothiazide, and the Combination: Implications for Clinical Practice. J Clinical Hypertension (Feb), 19(2): 143-50. doi:DOI: 10.1111/jch.12891
- Polsinelli VB, Satchidanand N, Singh R, Holmes D, Izzo JL. (2017) Hypertension and aging in rural Haiti: results from a preliminary survey. J Hum Hypertens (Feb), 31(2): 138-144.
- Gavish B and Izzo JL Jr. (2016) Arterial stiffness: going a step beyond. Am. J Hypertension (Nov), 29(11): 1223-1233. doi:doi: 10.1093/ajh/hpw061.
- 181. Tobe SW, Izzo JL, Jr. (2016) Controversies in hypertension: is lower blood pressure always better?. Journal of the American Society of Hypertension (Sep), 10: 618-20.
- 180. Izzo JL and Tobe SW. (2016) Renal denervation for human hypertension: is there a future?. Journal of the American Society of Hypertension. (Sep), 10: 390-2.
- Izzo JL, Jr., Tobe SW. (2016) Should age determine hypertension management? Recommendations from current guidelines. Journal of the American Society of Hypertension (Sep), 10: 7-9.
- Polsinelli V, Satchidanand N, Singh R, Holmes DM, Izzo JL. (2016) Hypertension and aging in rural Haiti: results from a preliminary survey. Journal of human hypertension (Jul), 2016: 1-7.
- Izzo JL, Jr., Tobe SW. (2016) Is there a preferred diuretic class for patients with renal impairment and hypertension?. Journal of the American Society of Hypertension (Mar), 10: 282-4.
- Tobe SW, Izzo JL, Jr. (2016) How should BP be measured in the office?. Journal of the American Society of Hypertension (Feb), 10: 189-90.
- Izzo, JL Jr. (2016) Age should not be a primary consideration in the management of hypertension. J American Soc Hypertension (Jan), 10: 12-15.
- Izzo J, Tobe S, Levy D. (2016) Controversies in hypertension: rationale and approach. Journal of the American Society of Hypertension (Jan), 10: 6.
- Izzo JL Jr; Khan SU; Saleem O; Osmond PJ. (2015) Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. J American Society of Hypertension. (Jul), 9(7): 526-35.
- Izzo JL Jr:. (2015) Response to "Central blood pressure physiology" a (more) critical review (Schultz et al.). American Journal of Hypertension (May), 28(5): 692.
- Izzo JL Jr. (2014) Brachial vs. central systolic pressure and pulse wave transmission indicators: a critical analysis. American J Hypertension. (Dec), 32(12): 2479-86.
- 167. Lewin AJ, Kereiakes DJ, Chrysant SG, Izzo JL Jr, Oparil S, Lee J, Fernandez V, Melino M. T. (2014) riple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. Ethnicity and Disease (Jan), 24(1): 41-7.
- Lewin AJ, Izzo JL Jr., MD, Melino M, Lee J, Fernandez V, Heyrman R. (2013) Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. Drugs and Aging (Sep), 30: 549-60.
- 165. Lam, Carolyn S.P, AM Shah, BA Borlaug, S Cheng, A Verma, J Izzo, S Oparil. GP Aurigemma, JD Thomas, B Pitt, MR Zile, SD Solomon. (2013) Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling and efficiency. European Heart Journal (Mar), 34(9): 676-83.
- Izzo JL, Yedlapati SH, Faheem SM, Younus U, Osmond PJ, Yedlapati S. (2012) Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. J Am Soc Hypertens (Nov), 6(6): 399-404.
- Chrysant SG, Littlejohn T, Izzo JL, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. (2012) Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs (Aug), 12(4): 233-243.
- Izzo JL. (2012) Value of combined thiazide-loop diuretic therapy in chronic kidney disease, heart failure and renin-angiotensin-aldosterone blockade. J Clin Hypertens (Greenwich) (May), 14(5): 344-344.
- Kereiakes DJ, Chrysant SG, Izzo JL, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. (2012) Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich) (Mar), 14(3): 149-157.
- Izzo JL, Weir MR. (2011) Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) (Sep), 13(9): 667-675.
- Izzo JL. (2011) Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg. Pol Arch Med Wewn (Sep), 121(9): 303-309.
- Wrobel MJ; Figge JJ; Izzo JL. (2011) Hypertension in diverse populations: a New York State Medicaid clinical guidance document. Journal of the American Society of Hypertension (Jul), 5: 208-229.
- Wrobel MJ, Figge JJ, Izzo JL. (2011) Hypertension in diverse populations: a New York State Medicaid clinical guidance document. J Am Soc Hypertens (Jul), 5(4): 208-229.
- Izzo JL, Zion AS. (2011) Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues. Ther Adv Cardiovasc Dis (Jun), 5(3): 169-178.
- Zion AS, Izzo JL. (2011) Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. Expert Rev Cardiovasc Ther (Apr), 9(4): 421-427.
- Izzo JL, Zion AS. (2011) Value of Angiotensin receptor blocker therapy in diabetes. J Clin Hypertens (Greenwich) (Apr), 13(4): 290-295.
- Hill MN, Miller NH, Degeest S, Materson BJ, Black HR, Izzo JL, Oparil S, Weber MA. (2011) Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens (Jan), 5(1): 56-63.
- Izzo JL. (2010) Are there benefits of antihypertensive therapy beyond blood pressure lowering?. Curr Hypertens Rep (Dec), 12(6): 440-447.
- Appel LJ, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. (2010) ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens (Mar), 4(2): 79-89.
- Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL, Oparil S, Weber MA. (2010) Combination therapy in hypertension. J Am Soc Hypertens (Mar), 4(2): 90-98.
- Bakris GL, Sowers JR, Glies TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. (2010) Treatment of hypertension in patients with diabetes--an update. J Am Soc Hypertens (Mar), 4(2): 62-67.
- Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. (2010) When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens (Mar), 4(2): 56-61.
- Appel LJ, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. (2009) ASH Position Paper: Dietary approaches to lower blood pressure. J Clin Hypertens (Greenwich) (Jul), 11(7): 358-368.
- Moser M, Izzo JL, Sica DA. (2007) The use of renin inhibitors in the management of hypertension. J Clin Hypertens (Greenwich) (Sep), 9(9): 701-705.
- Basile J, Black HR, Flack JM, Izzo JL. (2007) The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens (Greenwich) (Aug), 9(8): 636-645.
- Izzo JL. (2007) Prehypertension: demographics, pathophysiology, and treatment. Curr Hypertens Rep (Aug), 9(4): 264-268.
- Vyas M, Izzo JL, Lacourcière Y, Arnold JM, Dunlap ME, Amato JL, Pfeffer MA, Mitchell GF. (2007) Augmentation index and central aortic stiffness in middle-aged to elderly individuals. Am J Hypertens (Jun), 20(6): 642-647.
- Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevent. Circulation (May), 115(21): 2761-2788.
- Izzo JL, Mitchell GF. (2007) Aging and arterial structure-function relations. Adv Cardiol (Jan), 44: 19-34.
- Elliott WJ, Izzo JL. (2006) Device-guided breathing to lower blood pressure: case report and clinical overview. MedGenMed (Aug), 8(3): 23-23.
- Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Januszewicz A. (2006) Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens (Feb), 24(2): 403-408.
- Mitchell GF, Lacourcière Y, Arnold JM, Dunlap ME, Conlin PR, Izzo JL. (2005) Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension (Nov), 46(5): 1111-1117.
- Giles TD, Berk BC, Black HR, Cohn JN, Kostis JB, Izzo JL, Weber MA. (2005) Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (Sep), 7(9): 505-512.
- Izzo JL. (2005) Calcium channel blockers in hypertension. Is there still a controversy?. Aging Clin Exp Res (Aug), 17(4 Sup): 1-5.
- Izzo JL. (2005) Your drug, my drug, or our drugs: how aggressive should we be with antihypertensive therapy?. J Clin Hypertens (Greenwich) (Aug), 7(8 Sup): 5-7.
- Fernandez SF, Huang MH, Davidson BA, Knight PR, Izzo JL. (2005) Mechanisms of angiotensin II-mediated decreases in intraneuronal Ca2+ in calcium-loaded stellate ganglion neurons. Hypertension (Feb), 45(2): 276-282.
- Izzo JL. (2005) Pulse contour analysis and augmentation index: it's time to move beyond cuff blood pressure measurement. Am J Hypertens (Jan), 18(1 Pt): 1-2.
- Izzo JL, Gradman AH. (2004) Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am (Sep), 88(5): 1257-1271.
- Izzo JL. (2004) Arterial stiffness and the systolic hypertension syndrome. Curr Opin Cardiol (Jul), 19(4): 341-352.
- Izzo JL. (2003) Hypertension in the metabolic syndrome and diabetes: pathogenesis, clinical studies, and treatment. J Clin Hypertens (Greenwich) (Nov), 5(6 Sup): 3-10.
- Moser M, Izzo JL. (2003) Plasma renin measurement in the management of hypertension: the V and R hypothesis. J Clin Hypertens (Greenwich) (Nov), 5(6): 373-376.
- Fernandez SF, Huang MH, Davidson BA, Knight PR, Izzo JL. (2003) Modulation of angiotensin II responses in sympathetic neurons by cytosolic calcium. Hypertension (Jan), 41(1): 56-63.
- Izzo JL, Moser M. (2002) Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists. J Clin Hypertens (Greenwich) (Nov), 4(6 Sup): 11-19.
- Huang MH, Hu H, Plata ET, Yahia AM, Goldfarb AL, Izzo JL. (2002) Exceptional survival of a patient with large ventricular septal defect, bidirectional shunt, and severe pulmonary valve stenosis. J Am Soc Echocardiogr (Jun), 15(6): 665-667.
- Izzo JL, Manning TS, Shykoff BE. (2001) Office blood pressures, arterial compliance characteristics, and estimated cardiac load. Hypertension (Dec), 38(6): 1467-1470.
- Allen, K., Shykoff, B.E., Joseph Izzo. (2001) Pet ownership, but not ACE inhibitor therapy, blunts home blood pressure responses to mental stress. Hypertension (Jul), 38: 815-820.
- Joseph Izzo, Manning, T.S., Shykoff, B.E. (2001) Office blood pressures, arterial compliance characteristics, and estimated cardiac load. Hypertension (Jul), 38: 1467-1470.
- Joseph Izzo. (2001) Aging and systolic hypertension: cluster patterns and problem-solving strategies to answer the genetic riddle (editorial). Hypertension (Jul), 37: 1067-1068.
- Chow SL, Luzier AB, DiTusa L, Snyder BD, Izzo JL. (2001) Acid-suppressive therapy use associated with antihypertensive agents. J Clin Pharmacol (Jul), 41(7): 750-756.
- Chow, S.L., Luzier, A.B., DiTusa, L., Snyder, B.D., Joseph Izzo. (2001) Acid suppressive therapy use associated with antihypertensive agents. Pharmacoepidemiology (Jun), 41: 1-7.
- Allen K, Golden LH, Izzo JL, Ching MI, Forrest A, Niles CR, Niswander PR, Barlow JC. (2001) Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. Psychosom Med (May), 63(3): 487-492.
- DiTusa L, Luzier AB, Jarosz DE, Snyder BD, Joseph Izzo. (2001) Treatment of hypertension in a managed care setting. Am J Manag Care (May), 7(5): 520-524.
- Joseph Izzo, Shykoff, B.E. (2001) Arterial stiffness: clinical relevance, measurement, and treatment. Reviews in Cardiovascular Medicine (Apr), 2: 29-40.
- Izzo JL, Shykoff BE. (2001) Arterial stiffness: clinical relevance, measurement, and treatment. Rev Cardiovasc Med (Jan), 2(1): 29-34.
- Shykoff BE, Hawari FI, Izzo JL. (2001) Diameter, pressure and compliance relationships in dorsal hand veins. Vasc Med (Jan), 6(2): 97-102.
- Chaudhuri, A. and Izzo, J.L. Jr. (2001) Insulin resistance and hypertension in the absence of subcutaneous fat. Reviews in Cardiovascular Medicine (Jan), 1: 120-124.
- Izzo JL. (2000) The role of the renin-angiotensin system in vascular health: use of ACE inhibition to improve vascular function. Heart Dis (Sep), 2(5): 380-383.
- Izzo, J. (2000) A Challenge to JNC VI: Should guidelines for treatment be modified? Blood pressure guidelines and tight blood pressure control is essential. Medical Crossfire (Sep), 2(9): 45-57.
- Luzier AB, Forrest A, Feuerstein SG, Izzo JL, Schentag JJ. (2000) Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol (Sep), 86(5): 519-523.
- Izzo, J. (2000) Systolic hypertension, arterial stiffness and vascular damage: Role of the renin-angiotensin system. Blood Pressure Monitoring (Jun), 5(suppl): S7-S11.
- Joseph Izzo. (2000) Vascular disease and the renin-system in the patient with hypertension: panel discussion and questions to the audience. Blood Pressure Monitoring (Jun), 5(suppl): S27-S29.
- Izzo, J. (2000) The role of the renin-angiotensin system in vascular health. Use of ACE inhibition to improve vascular function. Heart Disease (May), 2(5): 380-383.
- Joseph Izzo, Levy D, Black HR. (2000) Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension (May), 35(5): 1021-1024.
- Luzier AB, Feuerstein SG, Uldrich P, Schentag JJ, Izzo JL Jr. (2000) Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization: A demonstration project. Am J Cardiol (Jan), 86: 519-523.
- Izzo JL. (2000) Systolic hypertension, arterial stiffness, and vascular damage: role of the renin-angiotensin system. Blood Press Monit (Jan), 5 Sup: 7-11.
- Hollenberg NK, Izzo JL, Sica DA, White WB, Mansoor GA. (2000) Vascular disease and the renin-angiotensin system in the patient with hypertension: panel discussion and questions from the audience. Blood Press Monit (Jan), 5 Sup: 27-29.
- Chaudhuri A, Izzo JL. (2000) Insulin resistance and hypertension in the absence of subcutaneous fat. Rev Cardiovasc Med (Jan), 1(2): 120-124.
- Sung BH, Izzo JL, Dandona P, Wilson MF. (1999) Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension (Jul), 34(1): 83-88.
- Bong Sung, Joseph Izzo, Dandona P, Wilson MF. (1999) Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension (Jul), 34(1): 83-88.
- Joseph Izzo, Taylor AA. (1999) The sympathetic nervous system and baroreflexes in hypertension and hypotension. Curr Hypertens Rep (Jun), 1(3): 254-263.
- Sung BH, Ching M, Izzo JL, Dandona P, Wilson MF. (1999) Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. J Hypertens (Apr), 17(4): 523-528.
- Bong Sung, Ching M, Joseph Izzo, Dandona P, Wilson MF. (1999) Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. J Hypertens (Apr), 17(4): 523-528.
- Huang MH, Knight PR, Joseph Izzo. (1999) Ca2+-induced Ca2+ release involved in positive inotropic effect mediated by CGRP in ventricular myocytes. Am J Physiol (Jan), 276(1 Pt): 259-264.
- Izzo JL. (1999) The hypertension primer project : An educational experiment. Hypertension (Jan), 33(1): 167-168.
- Huang, M., Knight, P., Joseph Izzo. (1999) Ionotropic mechanisms of calcitonin gene-related peptide in isolated ventricular myocytes. Am J Physiol (Jan), 276: R259-R264.
- Joseph Izzo. (1999) Risk stratification: a key to managing hypertension in the managed care setting. Am J Managed Care (Jan), 5(Suppl): S746-S751.
- Bong Sung, Joseph Izzo, Paresh Dandona, Michael Wilson. (1999) Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension (Jan), 34: 83-88.
- Izzo JL Jr. (1998) The microcirculation in hypertension. Current Concepts in Hypertension (Sep), 2(3): 1,2.
- Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Joseph Izzo. (1998) Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol (Aug), 82(4): 465-469.
- Sung BH, Ching M, Joseph Izzo, Dandona P, Wilson MF. (1998) Insulin-mediated venodilation is impaired in patients with high cholesterol. Hypertension (Jun), 31(6): 1266-1271.
- Joseph Izzo. (1998) The microcirculation in hypertension. Current Concepts in Hypertension (Mar), 2(3): 1-2.
- Ching MI, Sung BH, Forrest A, Wilson MF, Izzo JL. (1998) Vasoreactivity in pre- and postmenopausal women: evaluation by pharmacodynamic modeling. J Clin Pharmacol (Feb), 38(2): 151-159.
- Bong Sung, Ching, M., Joseph Izzo, Paresh Dandona, Michael Wilson. (1998) Insulin-mediated venodilation is impaired in patients with high cholesterol. Hypertension (Jan), 31: 1266-1271.
- Hawari, F., Shyoff, B., Joseph Izzo. (1998) Heparin attenuates norepinephrine-induced vasoconstriction by a cyclic-GMP-mediated mechanism. Vascular Medicine (Jan), 3: 95-100.
- Sung BH, Wilson MF, Izzo JL, Ramirez L, Dandona P. (1997) Moderately obese, insulin-resistant women exhibit abnormal vascular reactivity to stress. Hypertension (Oct), 30(4): 848-853.
- Sung BH, Wilson MF, Izzo JL, Ramirez L, Dandona P. (1997) Moderately obese, insulin-resistant women exhibit abnormal vascular reactivity to stress. Hypertension (Oct), 30(4): 848-853.
- Creager MA and Izzo JL Jr. (1997) Coronary and peripheral vasoreactivity: role of endothelial dysfunction. Current Concepts in Hypertension (Sep), 2(2): 2-3.
- Izzo JL Jr. (1997) Vasoreactivity and high-risk hypertension. Current Concepts in Hypertension (Sep), 2(2): 1-2.
- Sung BH, Izzo JL, Wilson MF. (1997) Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens (Jun), 10(6): 592-599.
- Carr JR, Fitzpatrick P, Izzo JL, Cumbo TJ, Birmingham MC, Adelman MH, Paladino JA, Hanson SC, Schentag JJ. (1997) Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. Infect Control Hosp Epidemiol (Apr), 18(4): 255-259.
- Creager, M.A., Joseph Izzo. (1997) Coronary and peripheral vasoreactivity: role of endothelial dysfunction. Current Concepts in Hypertension (Feb), 2(2): 2-3.
- Joseph Izzo. (1997) Vasoreactivity and high risk hypertension. Current Concepts in Hypertension (Feb), 2(2): 1-2.
- Harris LM, Faggioli GL, Shah R, Koerner N, Lillis L, Dandona P, Izzo JL, Snyder B, Ricotta JJ. (1995) Vascular reactivity in patients with peripheral vascular disease. Am J Cardiol (Jul), 76(3): 207-212.
- Grover A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P. (1995) Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension (Apr), 25(4 Pt): 779-784.
- Grover A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P. (1995) Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension (Apr), 25(4 Pt): 779-784.
- Perreault MM, Kazierad DJ, Wilton JH, Izzo JL. (1993) The effect of isradipine on theophylline pharmacokinetics in healthy volunteers. Pharmacotherapy (Mar), 13(2): 149-153.
- Izzo JL Jr. (1992) Cardiorenal interactions in regulation of blood pressure and volume. Choices in Cardiology (Sep), 6(Suppl 3): 5-9.
- O'Donovan RM, Gutierrez OH, Izzo JL. (1992) Preservation of renal function by percutaneous renal angioplasty in high-risk elderly patients: short-term outcome. Nephron (Jan), 60(2): 187-192.
- Joseph Izzo. (1992) Cardiorenal interactions in regulation of blood pressure and volume. Choices in Cardiology (Jan), 6(suppl): 5-9.
- Izzo JL, Swislocki AL. (1991) Workshop III--Insulin resistance: is it truly the link?. Am J Med (Feb), 90(2A): 26-31.
- Izzo JL, Larrabee PS, Sander E, Lillis LM. (1990) Hemodynamics of seasonal adaptation. Am J Hypertens (May), 3(5 Pt): 405-407.
- Izzo JL, Sander E, Larrabee PS. (1990) Effect of postural stimulation on systemic hemodynamics and sympathetic nervous activity in systemic hypertension. Am J Cardiol (Feb), 65(5): 339-342.
- Izzo JL. (1989) Sympathoadrenal activity, catecholamines, and the pathogenesis of vasculopathic hypertensive target-organ damage. Am J Hypertens (Dec), 2(12 Pt): 305-312.
- Izzo JL. (1989) The sympathoadrenal system: friend and foe?. Am J Hypertens (Dec), 2(12 Pt): 303-304.
- Scandling JD, Izzo JL, Pabico RC, McKenna BA, Radke KJ, Ornt DB. (1989) Potassium homeostasis during angiotensin-converting enzyme inhibition with enalapril. J Clin Pharmacol (Oct), 29(10): 916-921.
- Licht MR, Izzo JL. (1989) Humoral effect of norepinephrine on renin release in humans. Am J Hypertens (Oct), 2(10): 788-791.
- Hisa H, Chen YH, Radke KJ, Izzo JL, Sladek CD, Blair ML. (1989) Adrenergic control of renin during dietary sodium deprivation in conscious dogs. Am J Physiol (Jun), 256(6 Pt): 863-871.
- Sloand JA, Hooper M, Izzo JL. (1989) Effects of circulating norepinephrine on platelet, leukocyte and red blood cell counts by alpha 1-adrenergic stimulation. Am J Cardiol (May), 63(15): 1140-1142.
- Scandling JD, Izzo JL, Ricotta JJ, Paprocki S. (1989) Influence of cadaveric organ source on delayed renal allograft function. Transplantation (Feb), 47(2): 245-249.
- Chen YH, Hisa H, Radke KJ, Izzo JL, Sladek CD, Blair ML. (1988) Adrenergic control of renin in euhydrated and water-deprived conscious dogs. Am J Physiol (Dec), 255(6 Pt): 793-800.
- Joseph Izzo. (1988) Pathophysiology of "volume-dependent hypertension". IM - Internal Medicine for the Subspecialist (Dec)14-17.
- Joseph Izzo. (1988) Suitable and unsuitable agents for volume-dependent hypertension. IM - Internal Medicine for the Subspecialist (Dec)38-40.
- Joseph Izzo. (1988) Selective screening for renovascular disease. Diagnosis (Jan), 10: 55-64.
- Sundaresan PR, Guarnaccia MM, Izzo JL. (1987) Adrenal medullary regulation of rat renal cortical adrenergic receptors. Am J Physiol (Nov), 253(5 Pt): 1063-1067.
- Sloand JA, Izzo JL. (1987) Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med (Aug), 147(8): 1409-1412.
- Izzo JL, Licht MR, Smith RJ, Larrabee PS, Radke KJ, Kallay MC. (1987) Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension. Am J Cardiol (Aug), 60(4): 303-308.
- Izzo JL, Smith RJ, Larrabee PS, Kallay MC. (1987) Plasma norepinephrine and age as determinants of systemic hemodynamics in men with established essential hypertension. Hypertension (Apr), 9(4): 415-419.
- Izzo JL, Santarosa RP, Larrabee PS, Smith RJ, Kallay MC. (1987) Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine. J Cardiovasc Pharmacol (Jan), 10 Su: 225-229.
- Zambraski EJ, Ciccone CD, Izzo JL. (1986) The role of the sympathetic nervous system in 2-kidney DOCA-hypertensive Yucatan miniature swine. Clin Exp Hypertens A (Jan), 8(3): 411-424.
- Izzo JL, Thompson DA, Horwitz D. (1985) Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism. Life Sci (Sep), 37(11): 1033-1038.
- Blair ML, Chen YH, Izzo JL. (1985) Influence of renal perfusion pressure on alpha- and beta-adrenergic stimulation of renin release. Am J Physiol (Mar), 248(3 Pt): 317-326.
- Chen YH, Blair ML, Izzo JL. (1984) Renal norepinephrine overflow during graded renal nerve stimulation before and after beta-adrenoceptor blockade. J Auton Nerv Syst (Nov), 11(3): 285-295.
- Daugirdas JT, Ing TS, Chen WT, Vestal RE, Izzo JL, Hano JE, Norusis MJ. (1984) Hemodynamic response to volume depletion in acutely uremic dogs. Am J Physiol (Aug), 247(2 Pt): 229-236.
- Daugirdas JT, Ing TS, Chen WT, Vestal RE, Izzo JL, Hano JE, Norusis MJ. (1984) Hemodynamic responses to volume depletion in uremic dogs on maintenance hemodialysis. Am J Physiol (Aug), 247(2 Pt): H229-H236.
- Joseph Izzo. (1984) The sympathoadrenal system in maintenance of elevated arterial pressure. J Cardiovasc Pharm (Jun), 6: S514-S521.
- Izzo JL. (1984) The sympathoadrenal system in the maintenance of elevated arterial pressure. J Cardiovasc Pharmacol (Jan), 6 Sup: 514-521.
- Izzo JL, Sterns RH. (1983) Abnormal norepinephrine release in uremia. Kidney Int Suppl (Dec), 16: 221-223.
- Izzo JL, Ghosal A, Kwong T, Freeman RB, Jaenike JR. (1983) Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am J Cardiol (Oct), 52(7): 769-773.
- Izzo JL, Greulich D. (1983) Radioenzymatic assay for plasma dihydroxyphenylglycol (DHPG), dihydroxymandelic acid (DOMA) and dihydroxyphenylacetic acid (DOPAC). Life Sci (Aug), 33(5): 483-488.
- Colgan FJ, Sawa T, Teneyck LG, Izzo JL. (1983) Protective effects of beta blockade on pulmonary function when intracranial pressure is elevated. Crit Care Med (May), 11(5): 368-372.
- Izzo JL, Roncone AM, Kleiman F. (1983) Subcellular distribution of 125I-insulin by rat liver: specificity and regulatory factors. Am J Physiol (Mar), 244(3): 272-281.
- Joseph Izzo. (1983) Renovascular hypertension: diagnostic problems and therapeutic implications. JAMA (Jan), 249: 398-399.
- Joseph Izzo, Greulich, D. (1983) Radioenzymatic assay for plasma dihydroxyphenylglycol, dihydroxymandelic acid and dihydroxyphenyl acetic acid in plasma. Life Sci (Jan), 33: 483-488.
- Colgan, F.J., Sawa, T., Ten Eyck, L.G., Joseph Izzo. (1983) Protective effects of beta blockade on pulmonary function when intracranial pressure is elevated. Crit. Care Medicine (Jan), 11: 368-372.
- Joseph Izzo, Sterns, RH. (1983) Abnormal norepinephrine release in uremia. Kidney International (Jan), 24(Suppl): S221-S223.
- Joseph Izzo, Ghosal, A., Kwong, T., Freeman, R.B., Jaenike, J.R. (1983) Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am. J. Cardiology (Jan), 52: 769-773.
- Joseph Izzo. (1983) Cardiovascular hormonal effects of circulating norepinephrine. Hypertension (Jan), 5: 787-789.
- Izzo JL, Horwitz D, Lawton WJ, Keiser HR. (1983) Fludrocortisone suppression of sympathetic nervous activity. Clin Pharmacol Ther (Jan), 33(1): 102-106.
- Joseph Izzo, Horwitz, D., Lawton, W.J., Keiser, H.R. (1983) Fluorocortisone suppression of synpathetic nervous activity. Clin. Pharmacol. Ther. (Jan), 33: 102-106.
- Joseph Izzo, Izzo, MS, Sterns, RH, Freeman, RB. (1982) Sympathetic nervous hyperactivity in maintenance hemodialysis patients. Transactions American Society Artificial Internal Organs (Apr), 28: 528-533.
- Izzo JL, Izzo MS, Sterns RH, Freeman RB. (1982) Sympathetic nervous system hyperactivity in maintenance hemodialysis patients. Trans Am Soc Artif Intern Organs (Jan), 28: 604-607.
- Daugirdas, JT, Ing, TS, Chen, WT, Vestal, RE, Joseph Izzo, Hano, JE, Liu, P. (1982) Ultrafiltration hemodynamics in conscious, uremic dogs: effect of using a bicarbonate-buffered, plasma-resembling dialysate. Trans Am Soc Artif Int Organs (Jan), 28: 528-533.
- Joseph Izzo. (1982) Hypertension in the elderly: a pathophysiological approach to therapy. J Am Geriatrics Soc (Jan), 30: 352-359.
- Gutierrez OH, Izzo JL, Burgener FA. (1981) Transluminal recanalization of an occluded renal artery: reversal of anuria in a patient with a solitary kidney. AJR Am J Roentgenol (Dec), 137(6): 1254-1256.
- Goldstein DS, Feuerstein G, Izzo JL, Kopin IJ, Keiser HR. (1981) Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci (Feb), 28(5): 467-475.
- Goldstein DS, Harris AH, Izzo JL, Turkkan JS, Keiser HR. (1981) Response of plasma catecholamines and renin during operantly conditioned blood pressure elevations in baboons. Physiology and Behavior (Jan), 26(1): 33-37.
- Izzo JL, Horwitz D, Keiser HR. (1981) Physiologic mechanisms opposing the hemodynamic effects of prazosin. Clin Pharmacol Ther (Jan), 29(1): 7-11.
- Goldstein DS, Harris AH, Izzo JL, Turkkan JS, Keiser HR. (1981) Plasma catecholamines and renin during operant blood pressure conditioning in baboons. Physiol Behav (Jan), 26(1): 33-37.
- Izzo JL, Horwitz D, Keiser HR. (1979) Reduction in human urinary MHPG excretion by guanethidine: urinary MHPG as index of sympathetic nervous activity. Life Sci (Apr), 24(15): 1403-1406.
- Vinci JM, Zusman RM, Izzo JL, Bowden RE, Horwitz D, Pisano JJ, Keiser HR. (1979) Human urinary and plasma kinins: relationship to sodium-retaining steroids and plasma renin activity. Circ Res (Feb), 44(2): 228-237.
- Vinci JM, Zusman RM, Izzo JL, Bowden RE, Horwitz D, Pisano JJ, Keiser HR. (1979) Relationship of human urinary and plasma kinins to sodium-retaining steroids and plasma renin activity. Adv Exp Med Biol (Jan), 120B: 503-514.
- Vinci JM, Gill JR, Bowden RE, Pisano JJ, Izzo JL, Radfar N, Taylor AA, Zusman RM, Bartter FC, Keiser HR. (1978) The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest (Jun), 61(6): 1671-1682.
- Zambraski EJ, Ciccone CD, Izzo JL. (1900) The role of the sympathetic nervous system in 2-kidney DOCA-hypertensive Yucatan miniature swine. Clin Exp Hypertens A (Jan), 8(3): 411-424.
- Izzo JL, Izzo MS, Sterns RH, Freeman RB. (1900) Sympathetic nervous system hyperactivity in maintenance hemodialysis patients. Trans Am Soc Artif Intern Organs (Jan), 28: 604-607.
- Perreault MM, Kazierad DJ, Wilton JH, Izzo JL. (1900) The effect of isradipine on theophylline pharmacokinetics in healthy volunteers. Pharmacotherapy (Jan), 13(2): 149-153.
- Joseph Izzo. (1900) Systolic hypertension, arterial stiffness, and vascular damage: role of the renin-angiotensin system. Blood Press Monit (Jan), 5 Sup: 7-11.
- Hollenberg NK, Joseph Izzo, Sica DA, White WB, Mansoor GA. (1900) Vascular disease and the renin-angiotensin system in the patient with hypertension: panel discussion and questions from the audience. Blood Press Monit (Jan), 5 Sup: 27-29.
- Izzo JL. (1900) The sympathoadrenal system in the maintenance of elevated arterial pressure. J Cardiovasc Pharmacol (Jan), 6 Sup: 514-521.
- Vinci JM, Zusman RM, Izzo JL, Bowden RE, Horwitz D, Pisano JJ, Keiser HR. (1900) Relationship of human urinary and plasma kinins to sodium-retaining steroids and plasma renin activity. Adv Exp Med Biol (Jan), 120B: 503-514.
- O'Donovan RM, Gutierrez OH, Izzo JL. (1900) Preservation of renal function by percutaneous renal angioplasty in high-risk elderly patients: short-term outcome. Nephron (Jan), 60(2): 187-192.
- Allen K, Golden LH, Joseph Izzo, Ching MI, Forrest A, Niles CR, Niswander PR, Jared Barlow. (1900) Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. Psychosom Med (Jan), 63(3): 487-492.
- Hawari FI, Shykoff BE, Joseph Izzo. (1900) Heparin attenuates norepinephrine-induced venoconstriction. Vasc Med (Jan), 3(2): 95-100.
- Izzo JL, Santarosa RP, Larrabee PS, Smith RJ, Kallay MC. (1900) Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine. J Cardiovasc Pharmacol (Jan), 10 Su: 225-229.
- Shykoff BE, Hawari FI, Izzo JL. (1900) Diameter, pressure and compliance relationships in dorsal hand veins. Vasc Med (Jan), 6(2): 97-102.
- Izzo J. (1900) Cardiovascular hormonal effects of circulating norepinephrine. Hypertension (Jan), 5(5): 787-789.
Books and Book Chapters:
- Izzo JL Jr:. (2026) Chapter 33: Treatment of mild hypertension: an evolutionary process. In: in Current Therapy in Nephrology and Hypertension-3. Glassock RM, ed. Philadelphia: B.C. Decker,, 357-372.
- Fouad-Tarazi F and Izzo JL Jr. (2026) Hemodynamic profiles and responses. Ch. 45. In: Hypertension Primer, Second Edition. Izzo JL Jr. and Black HR, eds. Baltimore: Lippincott, Williams & Wilkins
- Izzo JL Jr. (2012) Hemodynamics. Chapter 1. In: Hypertension. Schiffrin EL and Touyz RM, eds. Future Science Group, 1-13.
- Fernandez SF, Srikakarlapudi S and Izzo Jr JL. (2012) Blood pressure variability. In: Blood pressure variability. Academic Press, NY, 355-357.
- Izzo JL Jr, Liebson P, Gorelick P, Reidy JJ. (2011) Assessment of Hypertensive Target Organ Damage. Chapter 15. In: Clinical Hypertension: a Companion to Braunwald’s Heart Disease (Second Edition). Black HR and Elliott W, eds. Philadelphia: Elsevier
- Izzo JL Jr, Srikakarlapudi S, and Fernandez SF. (2011) Blood pressure variation. Ch. 73. In: Primer on the Autonomic Nervous System, 3rd Edition. Robertson D, Biaggioni I, Burnstock G, and Low PA, Eds. NY: Academic Press, 355-8..
- Izzo JL Jr. (2010) Should prehypertension be treated? Ch 7. In: Evidence-based Management of Hypertension. Weir MR, ed. Gutenberg Press, 83-92..
- Parati G, Gavish B, Izzo JL Jr. (2008) Respiration and Blood Pressure. Chapter 43. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 136-9..
- Izzo JL Jr. (2008) Blood Pressure Variability and Reactivity. Chapter 56. In: Hypertension Primer, Fourth Edition. American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 177-81.
- Ruilope LM and Izzo JL Jr. (2008) Renal Risk. Chapter 80. In: Hypertension Primer, Fourth Edition. American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 261-5..
- Izzo JL Jr, Sica DA and Black HR. (2008) Initial Workup of Adults with Hypertension. Chapter 105. In: Hypertension Primer, Fourth Edition. American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 343-8..
- Izzo JL Jr, Giles TD and Materson BR. (2008) Defining the Syndrome of Hypertension. Chapter 107. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 351-6..
- Izzo JL Jr. (2008) Evaluation of arterial stiffness and central systolic pressure. Chapter 112. In: Hypertension Primer, Fourth Edition. American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 370-4..
- Black HR, Williams B and Izzo JL Jr. (2008) Evolution of American, European and British Hypertension Guidelines. Chapter 118. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 395-401.
- Izzo JL Jr, Black HR and Sica DA. (2008) Office Management of Hypertension. Chapter 119. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 370-4..
- Izzo JL Jr and Sica DA. (2008) Antihypertensive Drugs: Pharmacologic Principles and Dosing Effects. Chapter 128. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 2008. pp. 432-5.
- Black HR and Izzo JL Jr. (2008) Treatment of Prehypertension. Chapter 145. In: Hypertension Primer, Fourth Edition. Dallas: American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins, 483-5..
- Izzo JL Jr, Sica DA, and Black HR, editors. (2008) Hypertension Primer, Fourth Edition. American Heart Association. Philadelphia: Wolters-Kluwer/Lippincott, Williams & Wilkins.
- Izzo JL; Sica,D.A.; Black, H.R. (2008) Hypertension Primer, Fourth Edition. American Heart Association.
- Izzo JL Jr. (2007) Hemodynamics of Hypertension; Chapter 10. In: Comprehensive Hypertension. Hall, JE and Lip, GYH. Eds. Philadelphia: Mosby-Elsevier, 123-34.
- Izzo JL Jr., Liebson P, Gorelick P, Reidy JJ, and Mimran A. (2007) Assessment of Hypertensive Target Organ Damage. Chapter 15. In: Clinical Hypertension: a Companion to Braunwald’s Heart Disease, Black HR and Elliott W, eds. Philadelphia: Elsevier, 178-189.
- Izzo JL Jr and Mitchell GF. (2006) Aging and arterial structure-function relations. In: Advances in Cardiology: Atherosclerosis, Large Arteries and Cardiovascular Risk. Safar ME and Frohlich ED, Eds. Basel: Karger
- Izzo JL Jr. (2005) The sympathetic nervous system in acute and chronic blood pressure elevation. In: Hypertension: Companion to Brenner & Rector’s The Kidney, 2nd Edition. Oparil S and Weber MA, eds. Philadelphia, Elsevier-Saunders, 60-76..
- Izzo JL Jr and Fernandez SF. (2004) Biochemical assessment of sympathoadrenal activity. In: Primer on the Autonomic Nervous System, 2nd Edition. Robertson D, Biaggioni I, Burnstock G, and Low PA, Eds. NY: Academic Press, 234-238..
- Izzo JL Jr. (2004) Aging, Arterial Stiffness, and Systolic Hypertension. In: Hypertension in the Elderly: Prisant LM Ed. Totowa, New Jersey: Humana Press, 23-34..
- Parati G, Izzo JL Jr, Gavish B. (2003) Respiration and blood pressure. Ch. A40. In: Hypertension Primer, Third Edition. Izzo JL Jr and Black HR eds.,. Baltimore, Lippincott, Williams & Wilkins, 117-120..
- Izzo JL Jr. (2003) Stress responses and blood pressure reactivity. Ch. A42. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 123-125..
- Izzo JL Jr. (2003) Affective illness and hypertension. Ch. A56. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 159-160..
- Franklin SS and Izzo JL Jr. (2003) Aging, hypertension and arterial stiffness. Ch. A60. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 170-5.
- Izzo JL Jr and Pickering T. (2003) Diurnal and other cyclic variations of blood pressure. Ch. C113. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 334-336..
- Mitchell G and Izzo JL Jr. (2003) Evaluation of arterial stiffness. Ch. C119. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 351-355..
- Izzo JL Jr and Black H. (2003) Approach to the management of hypertension. Ch. C127. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 378-381..
- Kaplan N and Izzo JL Jr. (2003) Refractory hypertension. Ch. C128. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 381-384..
- Izzo JL Jr and Sica DA. (2003) Antihypertensive drugs: pharmacologic principles and dosing effects. Ch. C137. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins,, 405-408.
- Papademetriou V, Sica DA, and Izzo JL Jr. (2003) Thiazide and loop diuretics. Ch. C139. In: Hypertension Primer, Third Edition. Izzo JL Jr. and Black HR eds. Baltimore: Lippincott, Williams & Wilkins, 411-414..
- Izzo JL Jr and Campese V. (2003) Hypertension and renal disease. In: The Kidney. Brenner BM and Rector FC eds. Philadelphia: W.B. Saunders, 2109-38.
- Izzo JL Jr and Black HR, editors. (2003) Hypertension Primer, Third Edition. American Heart Association. Baltimore, Lippincott, Williams & Wilkins.
- Izzo JL; Black, H.R. (2003) Hypertension Primer, Third Edition. American Heart Association.
- Izzo JL Jr and Black HR, editors. (1999) Hypertension Primer, Second Edition. American Heart Association. Baltimore, Lippincott, Williams & Wilkins.
- Izzo JL Jr. (1999) Pathogenesis of left ventricular hypertrophy and diastolic dysfunction. Ch. 68. In: Hypertension Primer, Second Edition. Izzo JL Jr. and Black HR eds.,. Baltimore: Lippincott, Williams & Wilkins
- Izzo JL Jr. (1999) The sympathetic nervous system in acute and chronic blood pressure elevation. In: Hypertension: A Companion to Brenner & Rector’s The Kidney. Oparil S and Weber MA eds.,. Philadelphia: W.B. Saunders, 42-58..
- Izzo JL Jr. (1999) Variability in individual responses to antihypertensive drugs. Ch. 120. In: Hypertension Primer, Second Edition. Izzo JL Jr and Black HR, eds. Baltimore: Lippincott, Williams & Wilkins
- Sowers J and Izzo JL Jr. (1999) Endothelial dysfunction. Ch. 64. In: Hypertension Primer, Second Edition. Izzo JL Jr and Black HR, eds. Baltimore: Lippincott, Williams & Wilkins
- Izzo JL Jr. (1999) The sympathetic nervous system in human hypertension. Ch 43. In: Hypertension Primer, Second Edition. Izzo JL Jr and Black HR, eds. Baltimore: Lippincott, Williams & Wilkins
- Izzo JL, Black, H.R. (1999) Hypertension Primer, Second Edition. American Heart Institution.
- Izzo JL Jr. (1996) Biochemical assessment of sympathetic nervous activity. In: Primer on the Autonomic Nervous System: Robertson D, Low P, and Polinsky RJ, eds. San Diego: Academic Press, 116-122..
- Izzo JL Jr and Case DB. (1995) Drug treatment of hypertension. In: Essentials of Pharmacology. CM Smith and AM Reynard, Eds. Philadelphia: WB Saunders Co., 278-95.
- Khoury S and Izzo JL Jr. (1993) Chapter B26: Affective Disorders & Hypertension. In: Hypertension Primer, Izzo JL Jr. and Black HR, eds. Dallas: American Heart Association, 113-5.
- Keiser HR and Izzo, JL, Jr. (1993) Catecholamines & Target Organ Damage, Chapter B31. In: Hypertension Primer, Izzo JL Jr. and Black HR, eds. Dallas: American Heart Association, 123-5.
- Izzo JL Jr, Black HR, and Taubert K, editors. (1993) Hypertension Primer. American Heart Association, Dallas, Tx.
- Izzo JL Jr. (1993) Angioplasty for Renal Artery Stenosis, Chapter E33. In: Hypertension Primer, Izzo JL Jr. and Black HR. eds. Dallas: American Heart Association, 364-366..
- Joseph Izzo, Black, H.R., Taubert, K. (1993) Hypertension Primer. American Heart Association.
- Feld LG, Springate JE, Izzo JL Jr. (1990) Chapter 16: Special considerations in hypertension. In: Kidney Electrolyte Disorders. Chan JCM and Gill JA Jr, eds.,. New York: Churchill-Livingstone, 565-599..
- Izzo JL Jr:. (1989) Chapter 89: Labile hypertension, vasomotor instability and postural adaptation. In: Hypertension: Pathophysiology, Diagnosis and Management. Laragh JH and Brenner BR, eds. New York: Raven Press, 1415-1428..
- Joseph Izzo. (1983) In: Angiotensin converting enzyme inhibition. , 257-276.
- Izzo JL Jr. (1983) Chapter 17: Angiotensin converting enzyme inhibition. In: Recent Advances in Clinical Therapeutics, Volume 3; JY Yetiv and JJ Bianchine, eds.,. New York: Grune & Stratton, 1983, pp. 257-276., 257-276.
Professional Memberships:
- American Society of Hypertension; Ad hoc advisory group for organizational strategic planning (2013–present)
- American Society of Hypertension; Fellow of the American Society of Hypertension (2010–present)
- American Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, New York initiatives (2009–present)
- American Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, San Francisco initiatives (2008–present)
- American Society of Hypertension; Hypertension Education Development Group (2007–2010)
- American Society of Hypertension; Scientific Publications and Clinical Advisory Committee (2007–2009)
- American Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, New Orleans initiatives (2007–present)
- American Society of Hypertension; Treasurer (2006–2009)
- American Society of Hypertension; Executive Committee (2006–2009)
- American Society of Hypertension; Finance Committee (Chair) (2006–2009)
- American Heart Association - National Organization; Ischemic Heart Disease Guideline Development Group (2006–2007)
- American Society of Hypertension; Scientific Program Committee (2005–2008)
- American Society of Hypertension; Executive Council (2005–2006)
- American Society of Hypertension; Conflict of Interest Study Committee (2004–2006)
- American Society of Hypertension; Board of Directors (2003–2009)
- American Heart Association - Council for High Blood Pressure Research; Finance Committee (2003–2005)
- American Heart Association - National Organization; Medical Editorial Board (2002–present)
- American Society of Hypertension; Continuing Medical Education Committee (2001–2004)
- American Heart Association - Council for High Blood Pressure Research; Scientific Sessions Program Committee (2001–2004)
- American Heart Association - National Organization; Fellow of the American Heart Association (2001–present)
- United States Pharmacopeia; USP Counsel of Experts, Cardiovascular and Renal Drugs Expert Committee (2000–2005)
- American Society of Hypertension; National Specialist Examination Subcommittee (1999–2005)
- American Society of Hypertension; Specialist Committee (1999–2001)
- American Society of Hypertension; Nominating Committee (1999–2000)
- American Society of Hypertension; Professional Education Committee member (1998–2004)
- American Heart Association - National Organization; Continuing Education Committee (AHA National Committee) (1997–2000)
- American College of Physicians; Councilor for Upstate Region (New York State Chapter) (1996–2000)
- American Heart Association - Council for High Blood Pressure Research; Publications Committee (1996–1999)
- United States Pharmacopeia; USP Revisions Panel for Cardiorenal Drugs, 1995-2000 (1995–2000)
- American Heart Association - National Organization; Expert Panel on Cardiovascular Drugs (1994–2004)
- Council on Geriatric Cardiology; Fellow (1994–2000)
- American Society for Clinical Pharmacology and Therapeutics; Chairman, Hypertension Section (1994–1997)
- Buffalo Academy of Medicine; President (1994–1996)
- American Heart Association - Council for High Blood Pressure Research; Executive Committee member (1993–1996)
- American Heart Association - Council for High Blood Pressure Research; Long Range Planning Committee member (1993–1996)
- American Heart Association - Council for High Blood Pressure Research; Professional Education Committee Chairman (1993–1996)
- American Autonomic Society; Member (1992–2004)
- American Heart Association - Council for High Blood Pressure Research; Scientific Program Abstract Grader (1992–present)
- Society for Vascular biology and Medicine; Member (1990–2002)
- American Society for Clinical Pharmacology and Therapeutics; Co-Chairman, Hypertension Section (1990–1993)
- American Society for Clinical Pharmacology and Therapeutics; Abstract Reviewer (1990–1993)
- American Heart Association - Council for High Blood Pressure Research; Chairman, Hypertension Curriculum Committee (1990–1991)
- Association of Program Directors of Internal Medicine; Member (1988–2001)
- Buffalo Academy of Medicine; Member (1988–1998)
- American Society of Nephrology; Chairman, Hypertension Section (1987–present)
- American Heart Association - Council for High Blood Pressure Research; Professional Education Committee Member (1986–1993)
- American Society of Hypertension; Scientific Program Abstract Grader (1986–present)
- National Kidney Foundation of Upstate New York; Medical Advisory Board (1985–1987)
- National Kidney Foundation of Upstate New York; Chairman, Scientific Grant Review Committee (1985–1987)
- American Society of Nephrology; Scientific Program Abstract Grader (1984–1986)
- International Society for Hypertension; Member (1984–present)
- American Heart Association - Council for High Blood Pressure Research; Fellow (1983–present)
- American Society of Hypertension; Founding Member (1983–present)
- International Scoiety of Nephrology; member (1982–1993)
- New York Academy of Sciences; Member (1982–1984)
- American Heart Association - NYS Affiliate; Hypertension Committee (1982–1984)
- American Heart Association - Council on the Kidney in Cardiovascular Disease; Member (1982–present)
- American Association for the Advancement of Science; Member (1981–1984)
- American Federation for Biomedical Research; Member (1980–2000)
- Inter-American Society for Hypertension; Member (1980–present)
- American Society of Nephrology; Member (1979–2002)
Presentations:
- "Estrogen may influence blood pressure regulation" Thirteenth Scientific Meeting of the American Society of Hypertension; American Society of Hypertension (1998)
- "Normalization of hypertensive responses during ambulatory surgical stress by perioperative music" Thirteenth Scientific Meeting of the American Society of Hypertension (1998)
Service Activities:
- Combined ARB_neprolysin (LCZ) in Systolic Hypertension Combined ARB-neprolysin (LCZ) in Systolic Hypertension; International Principal Investigator and Chair,Executive Committee, Novartis Pharmaceuticals (2011–2013)
- Visiting Professorship New York University (Cardiology); Visiting Professor (2009)
- Visiting Professorship SUNY-Brooklyn (Medicine and Endocrinology); Visiting Professor (2008)
- Visiting Professorship Temple University (Cardiology); Visiting Professor (2008)
- TRINITY (Triple Combination therapy in Hypertension) TRINITY(Triple Combination therapy in Hypertension)Study Executive Committee and National Principal Investigator , Daiichi-Sankyo (2008–2010)
- Visiting Professorship University of Mississippi (Medicine and Pharmacology); Visiting Professor (2007)
- Visiting Professorship Tufts University (Cardiology); Visiting Professor (2007)
- Visiting Professorship Emory University (Cardiology and Medicine); Visiting Professor (2007)
- Visiting Professorship Tulane University (Physiology); Visiting Professor (2006)
- Visiting Professorship Medical College of Ohio (Medicine); Visiting Professor (2005)
- Visiting Professorship Yale University (Cardiothoracic Surgery); Visiting Professor (2004)
- Visiting Professorship University of Pittsburgh (Cardiology); Visiting Professor (2004)
- Visiting Professorship University of Rochester (Cardiology); Visiting Professor (2003)
- Visiting Professorship university of Rochester (Cardiology); Visiting Professor (2003)
- Visiting Professorship University of Rochester (Cardiology); Visiting Professor (2003)
- Visiting Professorship University Medical Center of South Neveda (Medicine); Visiting Professor (2003)
- Visiting Professorship George Washington University (Pharmacology); Visiting Professor (2003)
- Visiting Professorship SUNY at Syracuse (Nephrology); Visiting Professor (2003)
- Visiting Professorship University of Western Ontario (Clinical Pharmacology); Visiting Professor (2003)
- Visiting Professor SUNY-Brooklyn (Endocrinology), 12/01; Visiting Professor (2001)
- Visiting Professorship University of Western Ontario (Clinical Pharmacology); Visiting Professor (2001)
- Visiting Professor Mount Sinai School of Medicine (Hypertension), 2/01; Visiting Professor (2001)
- AMAZE AMAZE ("Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparison to Up-Titration of Lisinopril:A Multi-Center Trial Using Atacand-Zestril to Evaluate the Effects on Lowering Blood Pressure," National Lead Investigator; National Liaison (2001–2002)
- Faculty Senate; Member (2001–present)
- Visiting Professorship University of California, San Francisco (Cardiology) 12/00; Visiting Professor (2000)
- Visiting Professorship University of Western Ontario (Clinical Pharmacology); Visiting Professor (2000)
- Visiting Professorship University of Connecticut Health Center (Hypertension); Visiting Professor (2000)
- Visiting Professor Long Island Jewish Medical Center (General Medicine), 11/00; Visiting Professor (2000)
- Visiting Professorship Medical College of Wisconsin (Hypertension); Visiting Professor (2000)
- Visiting Professorship University of Connecticut Health Center (Hypertension); Visiting Professor (2000)
- Visiting Professorship SUNY at Syracuse (Nephrology); Visiting Professor (2000)
- Visiting Professorship University of Hawaii (Medicine); Visiting Professor (2000)
- Visiting Professorship University of Pittsburgh (Cardiology); Visiting Professor (2000)
- Visiting Professorship University of Edmonton (Cardiology); Visiting Professor (1999)
- Visiting Professorship University of Calgary (Cardiology and Physiology); Visiting Professor (1999)
- Visiting Professorship Rush Medical College (Preventive Medicine); Visiting Professor (1999)
- TROPHY (Trial of Prevention of Hypertension) (Trial of Prevention of Hypertension) Study, Data Safefty Monitoring Board, Astra Zeneca; Board Member (1999–2005)
- Editorial Board Reviews in Cardiovascular Medicine; Editorial Board Member (1999–2001)
- Sample Committee; Chair (1999–present)
- Editorial Board Journal of Clinical Hypertension; Editorial Board Member (1999–present)
- Sample Committee; Member (1999–present)
- Sample Committee; Member (1999–present)
- Visiting Professorship Wayne State University (Endocrinology); Visiting Professor (1998)
- Faculty Council; Alternate Member (1998–2002)
- Visiting Professorship Albany Medical College (Medicine); Visiting Professor (1997)
- Visiting Professorship Albany Medical College (Cardiology); Visiting Professor (1997)
- Visiting Professorship Northeastern Ohio Consortium (Medicine); Visiting Professor (1997)
- Visiting Professorship Susquehanna Health System (Medicine); Visiting Professor (1996)
- Visiting Professorship University of Illinois-Peoria (Clinical Pharmacology); Visiting Professor (1996)
- Ad Hoc Committee on Graduate Medical Education Refinancing; Member (1996–present)
- Visiting Professorship Albany Medical College (Cardiology and Medicine); Visiting Professor (1995)
- Visiting Professorship Meharry Medical College (Clinical Pharmacology); Visiting Professor (1994)
- New Service Activity Fellow, Council on Geriatric Cardiology; Member (1994–present)
- Visiting Professorship Albany Medical College(Cardiology); Visiting Professor (1993)
- Visiting Professorship Thomas Jefferson University (Clinical Pharmacology); Visiting Professor (1993)
- Visiting Professorship Tulane University (Cardiology); Visiting Professor (1993)
- Visiting Professorship University of Western Ontario (Clinical Pharmacology); Visiting Professor (1993)
- Visiting Professorship Northeastern Ohio Consortium (Medicine); Visiting Professor (1992)
- Visiting Professorship Pennsylvania State University (Nephrology); Visiting Professor (1992)
- Visiting Professorship Pennsylvania State University (Nephrology); Visiting Professor (1992)
- Visiting Professorship Yale University (Cardiology); Visiting Professor (1992)
- Visiting Professorship University of Michigan (Hypertension); Visiting Professor (1991)
- Visiting Professorship Medical College of Ohio (Medicine); Visiting Professor (1991)
- Visiting Professorship Albany Medical College (Cardiology and Medicine); Visiting Professor (1990)
- Clinical Service Hypertension Consultations (weekly, 1/2 day); Other (1990–present)
- Faculty Council; Member (1989–present)
- Visiting Professorship West Virginia University (Nephrology); Visiting Professor (1988)
- Clinical Service Attending Physician, General Medicine, 2 months per year; Volunteer (1988–present)
- Visiting Professorship Henry Ford Hospital (Nephrology); Visiting Professor (1987)
- Visiting Professorship SUNY at Syracuse (Nephrology); Visiting Professor (1987)
- Visiting Professorship University of California, San Diego (Nephrology); Visiting Professor (1986)
- Visiting Professorship University of Kansas (Nephrology); Visiting Professor (1986)
- Visiting Professorship Yale University (Hypertension); Visiting Professor (1986)
- Visiting Professorship Temple University (Nephrology); Visiting Professor (1985)
- Visiting Professorship John Hopkins University School of Medicine (Nephrology); Visiting Professor (1984)
- Visiting Professorship Rutgers University (Physiology); Visiting Professor (1983)
- Visiting Professorship Johns Hopkins University School of Medicine (Nephrology); Visiting Professor (1983)
- Visiting Professorship Cleveland Clinic Foundation (Hypertension); Visiting Professor (1983)
- Visiting Professorship Albany Medical College (Nephrology); Visiting Professor (1982)
- Visiting Professorship NHLBI, NIH (Experimental Therapeutics) 5/82; Visiting Professor (1982)